AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 302 min read$NTRA

Rabinowitz Matthew sold $448K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 1,718 shares of Natera, Inc. (NTRA) at $260.49 ($0.45M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not introduce new company performance information.

02

Market read

Insider selling can influence short-term sentiment, but the 10b5-1 structure suggests limited informational content.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or contract updates, the fundamental read-through is weak.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29, covering a sale dated 2026-07-27.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc. involving the executive chairman.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 1,718 shares in an open-market transaction on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 insider sale and explicitly notes a pre-arranged 10b5-1 plan, reducing signaling risk.

Market effects

Sector

Minimal. Insider sale disclosures rarely change sector fundamentals for diagnostics/oncology testing names.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale is under a pre-arranged 10b5-1 plan, so it may reflect liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Natera, Inc.

    Company whose executive chairman reported an open-market insider sale under a 10b5-1 plan.

  • insider
    Matthew Rabinowitz

    Executive Chairman and reporting person who sold 1,718 shares at $260.4908 on 2026-07-27.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min